Sign inSubmit
Tips: “quotes” for a phrase · author:Lee · a DOI goes straight to its article

53 results for “Clinical Trials”
Set a search alert
Research ArticleOpen accessIn the abstractDementia in Parkinson's Disease: A Clinical ReviewRenata Teles Vieira, Leonardo Caixeta, Sergio Machado, Marcelo CaixetaProblem statement: Idiopathic Parkinson's Disease (PD) has being increasingly seen as a neuropsychiatric entity and no longer purely neurological, given the frequency and exuberance with which the psychiatric manifestations occurs. Approach: This review will focus on the epidemiology, clinical aspects, differential diagnosis with Alzheimer's Disease (AD) associated with parkinsonism, Dementia with Lewy Bodies (LBD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration … …Neuroscience International, Vol. 2, Issue 1 · 23 Nov 2011 · 7,768 accessesView PDFCite
Research ArticleOpen accessIn the abstractUncommon Toxicologic Profile at Toxic Doses of CPI-613 (an Agent Selectively Alters Tumor Energy Metabolism) in Rats and Minipigs Reflects Novel MechanismClaudia Maturo, King C. Lee, Robert Rodriguez, Robert ShorrProblem statement: CPI-613 is a novel anticancer agent and the toxicological profile has not been assessed. Accordingly, the objective of these studies was to thoroughly evaluate the Toxicokinetic (TK) effects of CPI-613 in rats and to compare the toxicological profile of rats to minipigs to determine if there were differences between the two animal species. Approach: These studies involved assessments … …American Journal of Pharmacology and Toxicology, Vol. 5, Issue 4 · 13 Jun 2011 · 9,584 accessesView PDFCite
Research ArticleOpen accessIn the abstractComparisons of Test Statistics for Noninferiority Test for the Difference between Two Independent Binominal ProportionsYouhei Kawasaki, Fanghong Zhang, Etsuo MiyaokaProblem statement: Noninferiority tests are frequently used in clinical trials to demonstrate that the response for study drugs is not much worse than the response for reference drugs. Several test statistics exist. However, a detailed comparison of those test statistics is not researched. Moreover, a little complex calculation might be necessary in some of those test statistics. Approach: In this … …Current Research in Biostatistics, Vol. 1, Issue 1 · 30 Jun 2010 · 14,104 accessesView PDFCite
Review ArticleOpen accessIn the abstractScope and Perspectives of New TB Drugs and VaccinesJaishree Meena, Laxman S. MeenaTuberculosis remains a major threatening infectious disease claiming millions of lives every year; hence increasing the global burden of TB disease. Co-infection with human immuno-deficiency virus and emergence of multi-drug resistant tuberculosis, extremely drug resistant tuberculosis and totally drug resistant tuberculosis enhances deadly effect of tuberculosis. To eliminate TB disease from human population several partnerships are working together like Stop … …American Journal of Infectious Diseases, Vol. 11, Issue 3 · 10 Sep 2015 · 7,946 accessesView PDFCite
Research ArticleOpen accessIn the abstractTHREE BAYESIAN TEST INDEXES FOR NORMAL DISTRIBUTIONSYohei KawasakiIn clinical trials, data that are consistent with a normal distribution are often regarded as candidates for primary evaluation variables. In such cases, t-tests are frequently used to compare different groups of data. However, the repeated use of t-tests leads to problems with multiplicity. This study proposes three new indexes that are based on (Kawasaki and Miyaoka, 2012; 2013). These … …Journal of Mathematics and Statistics, Vol. 10, Issue 2 · 24 Apr 2014 · 6,725 accessesView PDFCite
Research ArticleOpen accessIn the abstractInfluence of Process Conditions on Measles Virus StabilityK. Weiss, D. Salzig, J. Gerstenberger et al.Recombinant measles viruses are currently tested in clinical trials as oncolytic agent to be applied in cancer therapy. Contrary to their use as vaccine where 103 infectious virus particles per dose are needed, for cancer therapy 109 virus particles should be provided per dose. This leads to other challenges for the production process when compared to vaccine production. This study … …American Journal of Biochemistry and Biotechnology, Vol. 9, Issue 3 · 21 Sep 2013 · 9,957 accessesView PDFCite
Research ArticleOpen accessIn the abstractBiomarker Quantitation: Analytical Considerations for Ligand Binding Assay Regression Curves and Quality Control SamplesMark DysingerAs biomarkers grow in relevance for both the design and support of therapeutics and the clinical trials associated with them, there is an ever increasing need for accurate quantitation of these biochemical entities in biological matrices. While quantifying many biotherapeutics via ligand binding assay platforms can be fairly straightforward, biomarkers present some unique challenges that must be taken into account … …American Journal of Immunology, Vol. 8, Issue 3 · 25 Aug 2012 · 8,030 accessesView PDFCite
Research ArticleOpen accessIn the abstractJapanese Encephalitis Virus: An Emerging PathogenSneham Tiwari, Sai V.P. Chitti, Asha Mathur, Shailendra K. SaxenaJapanese Encephalitis Virus (JEV) is a flavivirus maintained in a zoonotic cycle which involves pigs, birds and Culex species of mosquitoes causing fatal encephalitis endemic most of Asia and as far as Australia from its putative origin in Indonesia and Malaysia. The principle vector is Culex mosquito, most important being Culex tritaenorhynchus, present in greatest density in rainy season (June … …Current Research in Virology, Vol. 1, Issue 1 · 2 Aug 2012 · 14,904 accessesView PDFCite
Research ArticleOpen accessIn the abstractKEY PARAMETERS OF MEASLES VIRUS PRODUCTION FOR ONCOLYTIC VIROTHERAPYK. Weiss, D. Salzig, M. D. Mühlebach et al.Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic therapy can be more than a million times higher compared to vaccination. This requires highly effective production processes which guarantee the measles virus quantities needed for its use … …American Journal of Biochemistry and Biotechnology, Vol. 8, Issue 2 · 22 Jun 2012 · 9,791 accessesView PDFCite
Research ArticleOpen accessIn the abstractβ 1, 3-Glucan in Cancer TreatmentVaclav Vetvicka, J. VetvickovaNatural products, useful in preventing and/or treating various diseases, have been sought after throughout the man’s history. Despite some problems inherited from the natural source of glucans, there is extensive literature about their activities in animal tumor models. For the past 25 years, Japan has used several forms of mushroom-derived glucans in treating cancer patients. Additionally, close to twenty clinical … …American Journal of Immunology, Vol. 8, Issue 2 · 6 Jun 2012 · 8,880 accessesView PDFCite